Novogenia AG (ticker symbol: 7V0, formerly Darwin AG), an international healthcare company focused on human genetics and personalized products, announced the U.S. market launch of its new MGT Plus methylation test. This launch, in partnership with U.S.-based 10X Health, expands their joint product pipeline and reinforces their international collaboration in genetic analysis and longevity.
Methylation is a fundamental biochemical process involved in numerous metabolic and regulatory functions. It influences the function and processing of various biological molecules, including vitamins and neurotransmitters. While existing commercial tests analyze a limited number of genes, MGT Plus covers 27 genes across six interconnected biological pathways: energy and nutrient metabolism, stress and neurotransmitter regulation, vascular, immune, and cellular health. This broader scope provides a more comprehensive picture of methylation processes, offering deeper insights into key biochemical pathways.
“With MGT Plus, we are enabling a more comprehensive understanding of biochemical methylation processes,” said Dr. Daniel Wallerstorfer, CEO of Novogenia AG. “The expanded analysis provides deeper insights into genetic factors involved in methylation-related metabolic pathways, creating new opportunities for personalized prevention and health strategies. Our close collaboration with 10X Health underscores our commitment to making scientific innovations accessible internationally.”
The global direct-to-consumer testing market is growing rapidly, reaching approximately $4.7 billion in 2025 and projected to exceed $16.0 billion by 2033. Genetic testing represents the largest segment, accounting for over 40% of the market. North America leads this sector, contributing around 50% of the global market volume in 2025. This growth is driven by increasing interest in personalized health information and preventive care.
Novogenia's expanded product portfolio and strategic partnerships position it to capitalize on this trend. The company's in-house laboratory conducts genetic analyses used in disease diagnosis, treatment, and prevention, as well as in producing tailored nutritional supplements and cosmetics. Novogenia also collaborates with physicians, therapists, and fitness trainers to optimize patient care based on genetic predispositions.
For more information about Novogenia and its products, visit https://novogenia.com/novogenia-ag.
